Biomarker-enhanced triage in respiratory infections: A proof-of-concept feasibility trial

European Respiratory Journal

Volumn 42, Issue 4, 2013, Pages 1064-1075

  Albrich, Werner C ^a,b   Rüegger, Kristina ^a   Dusemund, Frank ^a,c   Schuetz, Philipp ^a   Arici, Birsen ^a   Litke, Alexander ^a   Blum, Claudine A ^a   Bossart, Rita ^d   Regez, Katharina ^d   Schild, Ursula ^d   Guglielmetti, Merih ^d   Conca, Antoinette ^d   Schäfer, Petra ^d   Schubert, Maria ^a   De Geest, Sabina ^a   Reutlinger, Barbara ^d   Irani, Sarosh ^d   Bürgi, Ulrich ^e   Huber, Andreas ^f   Müller, Beat ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Division of Infectious Diseases and Hospital Epidemiology   (Switzerland)

^c Division of Pneumology   (Switzerland)

^d NONE   (Switzerland)

^e Kantonsspital Aarau   (Switzerland)

^f CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROADRENOMEDULLIN;

ADULT; ADVERSE DRUG REACTION; ALGORITHM; ARTICLE; BREATHING RATE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEASIBILITY STUDY; FEMALE; HEALTH STATUS; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; PROGNOSIS; PUBLIC RELATIONS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELF CARE; SOCIAL PSYCHOLOGY; SYSTOLIC BLOOD PRESSURE;

ADRENOMEDULLIN; ADULT; AGED; ALGORITHMS; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEASIBILITY STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INTERVENTION STUDIES; LENGTH OF STAY; LINEAR MODELS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; RESPIRATORY TRACT INFECTIONS; RISK ASSESSMENT; TRIAGE;

EID: 84875814437     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00113612     Document Type: Article

References (49)

1. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369: 1179-1186.
2. Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in " low-risk" community acquired pneumonia. BMC Infect Dis 2003; 3: 11.
3. Griffiths PD, Edwards MH, Forbes A, et al. Effectiveness of intermediate care in nursing-led in-patient units. Cochrane Database Syst Rev, 2007: CD002214.
4. Chalmers JD, Al-Khairalla M, Short PM, et al. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 2010; 65: 608-618.
5. Aujesky D, McCausland JB, Whittle J, et al. Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia. Clin Infect Dis 2009; 49: e100-e108.
6. Baehni C, Meier S, Spreiter P, et al. Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. BMC Pulm Med 2010; 10: 12.
7. Choudhury G, Chalmers JD, Mandal P, et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J 2011; 38: 643-648.
8. Labarere J, Stone RA, Scott Obrosky D, et al. Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. J Gen Intern Med 2006; 21: 745-752.
9. McGregor MJ, Fitzgerald JM, Reid RJ, et al. Determinants of hospital length of stay among patients with pneumonia admitted to a large Canadian hospital from 1991 to 2001. Can Respir J 2005; 12: 365-370.
10. Menéndez R, Cremades MJ, Martínez-Moragón E, et al. Duration of length of stay in pneumonia: influence of clinical factors and hospital type. Eur Respir J 2003; 22: 643-648.
11. Schlarmann J. Der CMS im ePA. Verschiedene Qualitätsdimensionen eines Instruments. Eine empirische Analyse. [The CMS in ePA. Diverse Quality Dimensions of an Instrument. An Empirical Analysis.] PhD Thesis. Universität Witten/Herdecke, Gelsenkirchen, Germany, 2007.
12. Louis Simonet M, Kossovsky MP, Chopard P, et al. A predictive score to identify hospitalized patients' risk of discharge to a post-acute care facility. BMC Health Serv Res 2008; 8: 154.
13. Griffiths P, Edwards M, Forbes A, et al. Post-acute intermediate care in nursing-led units: a systematic review of effectiveness. Int J Nurs Stud 2005; 42: 107-116.
14. Griffiths P, Wilson-Barnett J. The effectiveness of "nursing beds": a review of the literature. J Adv Nurs 1998; 27: 1184-1192.
15. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011; 17: Suppl. 6, E1-E59.
16. Albrich WC, Dusemund F, Ruegger K, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011; 11: 112.
17. Chang CL, Sullivan GD, Karalus NC, et al. Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score. Respirology 2011; 16: 146-151.
18. Schuetz P, Koller M, Christ-Crain M, et al. Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. Epidemiol Infect 2008; 136: 1628-1637.
19. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in communityacquired pneumonia. Ann Emerg Med 2008; 52: 48-58.
20. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10: R96.
21. Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in communityacquired pneumonia. Chest 2009; 136: 823-831.
22. Krüger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010; 182: 1426-1434.
23. Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010; 14: R106.
24. Ronan D, Nathwani D, Davey P, et al. Predicting mortality in patients with community-acquired pneumonia and low CURB-65 scores. Eur J Clin Microbiol Infect Dis 2010; 29: 1117-1124.
25. Müller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Investig 2007; 37: 145-152.
26. Müller B, Süess E, Schuetz P, et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006; 260: 568-576.
27. Schuetz P, Stolz D, Mueller B, et al. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis 2008; 8: 22.
28. Albrich WC, Rüegger K, Dusemund F, et al. Optimised Patient Transfer using an Innovative Multidisciplinary Assessment in Kanton Aargau (OPTIMA I): an observational survey in lower respiratory tract infections. Swiss Med Wkly 2011; 141: w13237.
29. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax 2010; 65: 878-883.
30. Mandell LA. Severe community-acquired pneumonia (CAP) and the Infectious Diseases Society of America/ American Thoracic Society CAP guidelines prediction rule: validated or not. Clin Infect Dis 2009; 48: 386-388.
31. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72.
32. Dodd S, Bassi A, Bodger K, et al. A comparison of multivariable regression models to analyse cost data. J Eval Clin Pract 2006; 12: 76-86.
33. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of communityacquired pneumonia. Crit Care 2010; 14: 203.
34. Krüger S, Frechen D. Another brick in the wall: adrenomedullin and prognosis in community-acquired pneumonia. Eur Respir J 2012; 39: 1060-1061.
35. Krüger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31: 349-355.
36. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164: 396-402.
37. Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596-2602.
38. Krüger S, Welte T. Biomarkers in community-acquired pneumonia. Expert Rev Respir Med 2012; 6: 203-214.
39. Schuetz P, Müller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9: CD007498.
40. Mandell L. Decisions about treating community-acquired pneumonia. Ann Intern Med 2005; 142: 215-216.
41. Covinsky KE, Pierluissi E, Johnston CB. Hospitalization-associated disability: "she was probably able to ambulate, but I'm not sure". JAMA 2011; 306: 1782-1793.
42. Gill TM, Allore HG, Holford TR, et al. Hospitalization, restricted activity, and the development of disability among older persons. JAMA 2004; 292: 2115-2124.
43. Coley CM, Li YH, Medsger AR, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med 1996; 156: 1565-1571.
44. Carratalà J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med 2012; 172: 922-928.
45. Raut M, Schein J, Mody S, et al. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin 2009; 25: 2151-2157.
46. Chalmers JD, Akram AR, Hill AT. Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J 2010; 37: 858-864.
47. Loeb M, Carusone SC, Goeree R, et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. JAMA 2006; 295: 2503-2510.
48. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. JAMA 2000; 283: 749-755.
49. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059-1066.